Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 10, 2022 07:00 ET | Source: Oncorus, Inc.

Oncorus to Present at the Oppenheimer 32nd Annual Healthcare Conference

CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today...
March 09, 2022 07:00 ET | Source: Oncorus, Inc.

Oncorus Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates

Data presented from ongoing Phase 1 clinical trial of ONCR-177 in multiple solid tumor indications at RP2D at SITC 2021 and preclinical studies of ONCR-GBM targeting brain cancer at IOVC 2021Signed...
February 22, 2022 08:00 ET | Source: Oncorus, Inc.

Oncorus Announces Promotion of John Goldberg, M.D. to Chief Medical Officer

CAMBRIDGE, Mass., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today...
January 03, 2022 07:00 ET | Source: Oncorus, Inc.

Oncorus to Present at the H.C. Wainwright BioConnect Virtual Conference

CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (NASDAQ: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today...
November 23, 2021 07:00 ET | Source: Oncorus, Inc.

Oncorus to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today...
November 17, 2021 07:00 ET | Source: Oncorus, Inc.

Oncorus to Present at the Jefferies London Healthcare Conference

CAMBRIDGE, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today...
November 12, 2021 07:00 ET | Source: Oncorus, Inc.

Oncorus Reports Initial Safety, Tolerability, Immune Activation and Positive Clinical Response Data from its Ongoing Phase 1 Clinical Study of ONCR-177, its Lead Viral Immunotherapy Candidate, at SITC 2021

ONCR-177 was well tolerated with no dose-limiting toxicities in the surface lesion dose escalation part of the first-in-human study in heavily pretreated patients with advanced, injectable solid...
November 11, 2021 07:00 ET | Source: Oncorus, Inc.

Oncorus Announces Exclusive Licensing Agreement with Gaeta Therapeutics Ltd. for Use of Locally Delivered Interleukin-12 (IL-12) via Oncolytic Viral Expression in Combination with Immune Checkpoint Inhibitors

CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today...
November 09, 2021 08:00 ET | Source: Oncorus, Inc.

Oncorus Announces Details of Upcoming ONCR-177 Phase 1 Initial Clinical Data Presentation at the Society for Immunotherapy of Cancer’s (SITC) 2021 Annual Meeting

CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapy company focused on driving innovation to transform outcomes for cancer patients, today...
November 03, 2021 07:00 ET | Source: Oncorus, Inc.

Oncorus Reports Third Quarter 2021 Financial Results and Provides Business Updates

To report initial data from ongoing Phase 1 clinical trial of lead oncolytic Herpes Simplex Virus (oHSV) viral immunotherapy candidate, ONCR-177, in multiple solid tumor indications at the upcoming...